Durability of First Line Antiretroviral Therapy: Reasons and Predictive Factors for Modifications in a Swaziland Cohort

Simbarashe Takuva^1,2,5*, Goedele Louwagie¹, Khangelani Zuma^2,3 and Velephi Okello⁴

¹University of Pretoria, Faculty of Health Sciences, School of Health Systems and Public Health, Pretoria, South Africa, E-mail: stakuva@witshealth.co.za

²Mbabane Government Hospital Antiretroviral Therapy Unit, Ministry of Health and Social Welfare, Mbabane, Swaziland, E-mail: stakuva@witshealth.co.za

³HIV/AIDS, STIs and TB (HAST), Human Sciences Research Council, Pretoria, South Africa, E-mail: stakuva@witshealth.co.za

⁴Swaziland National AIDS Program, Ministry of Health and Social Welfare, Mbabane, Swaziland, E-mail: stakuva@witshealth.co.za

⁵Clinical HIV Research Unit, Wits Health Consortium, Johannesburg, South Africa, E-mail: stakuva@witshealth.co.za

^*Corresponding Author: Dr. Simbarashe Takuva, Epidemiology and Biostatistics Division, Clinical HIV Research Unit, Wits Health Consortium, Private Bag X 2600, Houghton, Johannesburg 2041, South Africa, Tel: +27112768800, Fax: +27114822130 Email: